Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
Conclusion: In this study, a PSA decline of greater than or equal to 50% after treatment with 225Ac-PSMA-617 was proven by multivariate analyses to be significantly associated with OS and PFS. Furthermore, previous 177Lu-PSMA treatment was negatively associated with PFS in both univariate and multivariate analyses.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., Lengana, T., Giesel, F. L., Van de Wiele, C., Morgenstern, A. Tags: Clinical Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Hepatocellular Carcinoma | Legislation | Liver | Liver Cancer | Nuclear Medicine | Prostate Cancer | Radiation Therapy | Renal Failure | Study | Toxicology | Urology & Nephrology | Xerostomia